MAYUMI NAKAGAWA, MD
Medical Practice at Markham St, Little Rock, AR
License number
Arkansas E-4193
Category
Medical Practice
Type
Blood Banking & Transfusion Medicine
License number
Arkansas E-4193
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
4301 W Markham St #783, Little Rock, AR 72205
Phone
(501) 686-8000
Personal information
See more information about MAYUMI NAKAGAWA at radaris.comName
Address
Phone
Little Rock, AR
17 Village Grove Rd, Little Rock, AR 72211
Professional information
Dr. Mayumi Nakagawa, Little Rock AR - MD (Doctor of Medicine)
Specialties:
Clinical Pathology
Address:
UAMS Transfusion Medicine
4301 W Markham St, Little Rock 72205
(501) 603-1178 (Phone)
4301 W Markham St, Little Rock 72205
(501) 603-1178 (Phone)
Certifications:
Clinical Pathology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UAMS Transfusion Medicine
4301 W Markham St, Little Rock 72205
Uams Medical Center
4301 West Markham St, Little Rock 72205
4301 W Markham St, Little Rock 72205
Uams Medical Center
4301 West Markham St, Little Rock 72205
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1990
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1990
Mayumi Nakagawa, Little Rock AR
Specialties:
Pathologist
Address:
4301 W Markham St, Little Rock, AR 72205
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Human Papilloma Virus Peptide-Specific T-Cell Response For Treatment Of Warts
US Patent:
2012004, Feb 23, 2012
Filed:
Aug 11, 2011
Appl. No.:
13/136801
Inventors:
Mayumi Nakagawa - Little Rock AR, US
Kevin Kim - Saint Louis MO, US
Thomas Horn - Brookline MA, US
Kevin Kim - Saint Louis MO, US
Thomas Horn - Brookline MA, US
International Classification:
A61K 39/12, C07K 7/08, C07K 7/06, A61P 31/20, A61K 38/19, A61K 38/21, A61K 38/20, A61P 35/00, C07K 14/025, A61K 39/165
US Classification:
424 852, 530324, 530325, 530326, 530327, 530328, 4241861, 424 851, 424 857, 424 856, 424 855
Abstract:
The inventors have treated human patients for warts by intralesional injection of antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) found in and causing the warts. It was found that the patients showed a response to HPV type 57 L1 peptide 380-412 (a peptide consisting of amino acid residues 380-412 of the protein L1) and HPV type 57 protein E4 (E4 10-30). One embodiment of the invention provides a pharmaceutical composition comprising a polypeptide comprising (a) L1 380-412 (SEQ ID NO:3) or a fragment of at least 8 residues of SEQ ID NO:3 or (b) E4 10-30 (SEQ ID NO:4) or a fragment of at least 8 residues of E4 10-30 (SEQ ID NO:4), wherein the composition is immunogenic in humans.
Hpv E6 Protein T Cell Epitopes And Uses Thereof
US Patent:
2011029, Dec 1, 2011
Filed:
Aug 4, 2011
Appl. No.:
13/136557
Inventors:
Mayumi Nakagawa - Little Rock AR, US
International Classification:
A61K 39/12, G01N 33/569, A61P 31/20, C12Q 1/02
US Classification:
4241861, 435 29, 435 792
Abstract:
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.
Cd8 T Cell Epitopes In Hpv 16 E6 And E7 Proteins And Uses Thereof
US Patent:
2006018, Aug 17, 2006
Filed:
Jan 31, 2006
Appl. No.:
11/343606
Inventors:
Kevin Kim - Little Rock AR, US
Mayumi Nakagawa - Little Rock AR, US
Anna-Barbara Moscicki - San Francisco CA, US
Mayumi Nakagawa - Little Rock AR, US
Anna-Barbara Moscicki - San Francisco CA, US
International Classification:
A61K 39/12, C12Q 1/70
US Classification:
424204100, 435005000
Abstract:
The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to induce strong CD8 T cell response and therefore, are important as sources of antigens for dendritic cell immunotherapy to treat cervical cancer. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of HLA types so that they can be used in concert to develop a preventative vaccine, which can be used for general population.
Hpv E6 Protein T Cell Epitopes And Uses Thereof
US Patent:
2009013, May 28, 2009
Filed:
Oct 2, 2008
Appl. No.:
12/286822
Inventors:
Mayumi Nakagawa - Little Rock AR, US
International Classification:
A61K 39/12, C12Q 1/02, A61K 35/12, A61K 39/00, A61K 31/7088
US Classification:
4241861, 435 29, 424 9371, 4241851, 514 44
Abstract:
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.
Human Papilloma Virus Dominant Cd4 T Cell Epitopes And Uses Thereof
US Patent:
2009011, May 7, 2009
Filed:
Sep 24, 2008
Appl. No.:
12/284704
Inventors:
Mayumi Nakagawa - Little Rock AR, US
Alessandro D. Santin - Little Rock AR, US
Alessandro D. Santin - Little Rock AR, US
International Classification:
A61K 39/12, C12Q 1/02, C07K 7/00, A61K 38/08, A61K 38/16, C07K 14/00, A61K 35/12
US Classification:
4241861, 435 29, 424 937, 530328, 530324, 514 15, 514 13
Abstract:
Provided herein are methods of determining immunodominant T cell epitopes within a protein expressed in an individual and immunotherapy directed towards a protein in an individual using these determined epitopes. The method comprises administering autologous dendritic cells pulsed with a recombinant protein to the individual, establishing T-cell lines therefrom and incubating the T cell lines with representative peptides from the protein to measure and identify those peptides from the protein inducing the T cell response. Also provided are synthetic or recombinant peptides or immunogenic compositions thereof comprising the identified peptide(s) or peptides of similar sequence and a method of preventing or treating a pathophysiological condition.